Short Interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Declines By 16.2%

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) saw a significant decline in short interest in February. As of February 13th, there was short interest totaling 540,151 shares, a decline of 16.2% from the January 29th total of 644,912 shares. Approximately 1.7% of the company’s stock are short sold. Based on an average trading volume of 143,301 shares, the short-interest ratio is presently 3.8 days. Based on an average trading volume of 143,301 shares, the short-interest ratio is presently 3.8 days. Approximately 1.7% of the company’s stock are short sold.

Oramed Pharmaceuticals Price Performance

Shares of NASDAQ ORMP traded down $0.18 during trading hours on Thursday, hitting $3.44. 35,473 shares of the stock were exchanged, compared to its average volume of 242,160. Oramed Pharmaceuticals has a one year low of $1.82 and a one year high of $3.76. The company’s 50 day moving average is $3.33 and its 200 day moving average is $2.77. The firm has a market capitalization of $136.92 million, a P/E ratio of 2.73 and a beta of 1.31.

Oramed Pharmaceuticals Announces Dividend

The firm also recently disclosed a dividend, which was paid on Monday, January 26th. Investors of record on Friday, January 16th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Friday, January 16th. Oramed Pharmaceuticals’s payout ratio is currently 19.84%.

Institutional Trading of Oramed Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd lifted its holdings in shares of Oramed Pharmaceuticals by 59.9% during the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company’s stock worth $109,000 after buying an additional 14,297 shares during the last quarter. Quadrature Capital Ltd bought a new position in Oramed Pharmaceuticals during the fourth quarter worth $119,000. HRT Financial LP acquired a new position in Oramed Pharmaceuticals during the 4th quarter valued at $131,000. Jane Street Group LLC raised its stake in Oramed Pharmaceuticals by 35.3% during the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock valued at $144,000 after purchasing an additional 17,510 shares during the last quarter. Finally, Squarepoint Ops LLC boosted its holdings in Oramed Pharmaceuticals by 95.1% in the 4th quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 28,406 shares during the period. Institutional investors and hedge funds own 12.73% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Oramed Pharmaceuticals in a research note on Monday, December 29th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.